Semax
Russian synthetic heptapeptide derived from ACTH; nootropic and neuroprotective claims.
Start with a product
Pick what you have. We'll guide the rest.
Schedule, what to expect, side-effects to watch — built around your exact product.
Russian synthetic heptapeptide derived from ACTH; nootropic and neuroprotective claims.
Evidence Intelligence Score™
- Preclinical
- Pilot human← current
- RCT
- Multi-RCT
- Meta-analysis
Confidence aggregates eight dimensions of evidence — human data, safety maturity, mechanism, clinical readiness, momentum, consistency, long-term follow-up, and translational signal. It is a measure of what is known, not a recommendation. Methodology.
- Human evidenceWeight of RCT and observational data6.3
- Safety maturityFollow-up depth and adverse-event signal5.3
- Mechanism confidencePathway specificity and clarity6.4
- Clinical readinessDistance to physician-prescribable use5.4
- Research momentumRecency of indexed clinical evidence5.0
- Study consistencyEffect direction across cohorts3.0
- Long-term dataFollow-up beyond initial trial windows3.6
- Translational confidenceAnimal → human signal preservation6.1
Early human signals exist, primarily from observational and pilot work — directional, not definitive.
Translational confidence is limited until pre-registered human trials reproduce the preclinical signal.
Interactions outside listed contraindications, long-term safety, and effect heterogeneity across age and sex are not fully resolved.
Outlook: directional. The next 12–24 months of registered trials will determine whether the early signal holds.
Cognition & focus
2 studies- weakAshmarin IP, Nezavibatko VN, Levitskaya NG, et al.
Intranasal Semax (heptapeptide ACTH 4-10 analog) showed nootropic effects on attention and memory in humans and improved recovery in ischemic stroke patients.
Observational1995unreviewed - weakMedvedeva EV, Dmitrieva VG, Povarova OV, et al.
Semax modulates BDNF and dopaminergic systems; clinical use in Russia for ischemic stroke and cognitive disorders with reported attention and memory improvements.
Preclinical2014unreviewed
Mood regulation
1 study- weakEremin KO, Kudrin VS, Saransaari P, et al.
Semax increases extracellular dopamine and serotonin metabolism in rat striatum and frontal cortex, supporting reported antidepressant/anxiolytic-like effects.
Preclinical2005unreviewed
Cognition & focus
1 regimenGenerally well tolerated; mild local nasal irritation reported. Not approved outside Russia/CIS.
Outpatient cognitive courses typically 10–14 days; stroke protocols 5–10 days.
Mood regulation
1 regimenMild nasal irritation; long-term safety not established.
Limited human mood-specific RCT data; mechanism supported by preclinical neurochemistry.
These are observed research regimens drawn from approved labels, clinical trials, or preclinical literature — not dosing recommendations. Suggestive, never prescriptive.
- —Long-term safety beyond reported study durations.
- —Effect size in populations under-represented in the cited trials.
- —Interactions with concomitant medications outside listed contraindications.
We surface uncertainty next to every claim. Suggestive, never prescriptive — discuss with a clinician.
1 brand across three tiers.
Research-use only
1 brandSold by chemical suppliers labelled 'for laboratory research only — not for human consumption'. No pharmaceutical-grade QC, no medical oversight. Listed for transparency.